RxDoctor Payments Data

Derrell Spurlock, OD

Optometrist · Minden, LANPI 1376506063

Payments from drug & device makers

$3,546in general payments, 2019–2025

Across 45 payments — averaging $78.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$837
  • Tarsus Pharmaceuticals, Inc.$471
  • Optos, Inc.$425
  • Oyster Point Pharma, Inc.$386
  • Sight Sciences, Inc.$271
  • AbbVie$254
  • plus $901 from 7 others

What the payments were for

  • Food & beverage$3,23991%
  • Entertainment$3079%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,546 in reported general payments places this provider in the 75th percentile of 500 optometrist providers in Louisiana.

See all optometrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$115,277
Medicare patients
788
Services billed
1,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner23$42,893
RestasisCyclosporine32$26,471
XiidraLifitegrast23$19,686
LumiganBimatoprost42$14,142
Travoprost37$5,870
Latanoprost541$3,998
SimbrinzaBrinzolamide/Brimonidine Tart15$3,096
Tobramycin-DexamethasoneTobramycin/Dexamethasone60$2,969
Ketorolac Tromethamine111$2,031
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat96$1,537
Prednisolone Acetate25$723
Timolol Maleate43$707
Brimonidine Tartrate73$631
Minocycline Hcl54$591
ErythromycinErythromycin Base49$585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$471$42,89323 claims
AbbVieRestasis, Lumigan$254$40,61374 claims
AlconSimbrinza$837$3,09615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 500 optometrist providers in Louisiana.

Other optometrist in Minden

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →